

iShares Genomics Immunology and Healthcare ETF
IDNA | NYSE Arca
Semi-Annual Shareholder Report — January 31, 2026



This semi-annual shareholder report contains important information about iShares Genomics Immunology and Healthcare ETF (the “Fund”) for the period of August 1, 2025 to January 31, 2026. You can find additional information about the Fund at blackrock.com/fundreports. You can also request this information by contacting us at 1-800-iShares (1-800-474-2737).

What were the Fund costs for the last six months?

(based on a hypothetical \$10,000 investment)

Fund name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
iShares Genomics Immunology and Healthcare ETF	\$28	0.47% ^(a)

^(a) Annualized.

Key Fund statistics

Net Assets.....	\$142,806,356
Number of Portfolio Holdings.....	55
Portfolio Turnover Rate.....	39%

What did the Fund invest in?

(as of January 31, 2026)

Industry allocation		Geographic allocation	
Industry	Percent of Total Investments ^(a)	Country/Geographic Region	Percent of Total Investments ^(a)
Biotechnology.....	63.8%	United States.....	59.1%
Pharmaceuticals.....	33.7	Germany.....	9.5
Life Sciences Tools & Services.....	2.5	France.....	8.5
		Japan.....	6.3
		Switzerland.....	4.4
		United Kingdom.....	4.1
		Denmark.....	3.8
		China.....	2.1
		Canada.....	0.9
		South Korea.....	0.7
		Iceland.....	0.6

^(a) Excludes money market funds.

Additional information

If you wish to view additional information about the Fund, including but not limited to financial statements, the Fund’s prospectus, and proxy voting policies and procedures, please visit blackrock.com/fundreports. For proxy voting records, visit blackrock.com/proxyrecords.

